As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions to the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).
Similar Posts
Breathing Circuit Set Recall: Hamilton Medical, Inc. Removes Coaxial Breathing Circuit Set Due to Possible Inner Blue Tube Cracks That May Impact Ventilation
Hamilton Medical is recalling certain coaxial breathing sets due to a defect that may cause cracks in the inner tube, risking patient rebreathing exhaled gases.Internet Pharmacy Warning Letters
Rogue online pharmacies offer potentially dangerous prescription drugs to U.S. consumers. FDA has issued warning letters informing the website operators that they are engaged in illegal activity in violation of the U.S. Federal Food, Drug, and Cosmetic ActMaiva Pharma Private Limited – 2/20/2026
Maiva Pharma Private Limited – 2/20/2026. Country: India. Record Type: 483Human Drug Compounding
Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.HimGo may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use HimGo, a product promoted and sold for sexual enhancement on various websites, including ebay.com, and possibly in some retail stores.Gerber Products Company Announces Voluntary Recall of Limited Batches of Arrowroot Biscuits Out of an Abundance of Caution Due to Potential Presence of Foreign Material Following Supplier Recall
January 26, 2026 — Gerber Products Company is initiating a voluntary recall of limited batches of Gerber® Arrowroot Biscuits out of an abundance of caution due to the potential presence of soft plastic and/or paper pieces that should not be consumed. The material comes from an arrowroot flour suppli